Â
- Chronic Fatigue Syndrome:
BiomedReports: The Plot Thickens for HEMISPHERx Biopharma (AMEX:HEB)
BioMedReports, the news portal covering the biomedical news is reporting on the reaction to a controversial news article that sent shares of Hemispherx Biopharma plunging late Thursday afternoon. Immediate reaction from the investment community led BioMedReports to interview the CEO of the company, Dr. William Carter, and as a result, both investors and patients of chronic fatigue syndrome will want to read some of the explosive details highlighted by the new report.
Hemispherx’s CFS Drug Is a Long Shot
Too many red flags are flying over Hemispherx Biopharma(HEB Quote) to be confident in the pending U.S. approval of the company’s drug for chronic fatigue syndrome. Retail investors are looking for the next biotech long shot to pay off just like Vanda Pharmaceuticals(VNDA Quote) did with the surprise approval of its schizophrenia drug. And so they’ve selected Hemispherx, a micro-cap drug company waiting for the U.S. Food and Drug Administration to render an approval decision on Ampligen for the treatment of patients with chronic fatigue syndrome (CFS).
- Fibromyalgia:
Fibromyalgia: Patients say many doctors don’t take them seriously
Asked to describe the seemingly indescribable, to make real the manifestations of a medical condition that some still doubt even exists, fibromyalgia patients often rely on similes of the most wince-inducing sort.  “I felt like acid was going through my veins.”  “It was like a steamroller ran over me.”  “Fatigue like someone’s pulled out your battery pack.”  “… as if someone pinged me with a hammer all over my body.”
International Non-Profit Brings Integrated Disability Management to Portland
The Disability Management Employer Coalition (DMEC), the only non-profit devoted to integrated disability and absence management, will conduct its 14th Annual International Conference July 19 †22, 2009 in Portland, Oregon. This employer-driven event attracts hundreds of attendees from around the world. This year’s conference has a focus on fiscal responsibility and legal compliance that can help companies compete in a tough economy.
Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis
To study the association of the presence of fibromyalgia (FM) with the Disease Activity Score in 28 joints (DAS28), the Health Assessment Questionnaire (HAQ), and the Medical Outcomes Study Short Form 36 (SF-36) health survey in patients with rheumatoid arthritis (RA).
Addition of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms in Patients Who Responded Only Partially to Previous GAD Treatments
The addition of Pfizer’s Lyrica® (pregabalin) capsules CV to other generalized anxiety disorder (GAD) treatments significantly improved the symptoms of the condition in patients who responded only partially to previous treatments, according to a study presented today at the American Psychiatric Association annual meeting in San Francisco, Ca. In this study, patients treated with Lyrica showed significant improvements in both their psychological and physical symptoms of anxiety.
0
0
0
Join the Discussion.